. Author manuscript; available in PMC: 2008 Jul 1.

Published in final edited form as: Drug Metab Dispos. 2008 Mar 31;36(7):1242–1248. doi: 10.1124/dmd.108.020396

Table 1.

Prevalence of CYP2C9*2 and CYP2C9*3 alleles in the study population (individuals screened for genotype, prior to inclusion in the pharmacokinetic study).

	Number of Subjects (n = 187)^†
SNPs	Homozygous	Heterozygous
CYP2C9*2	2	23
CYP2C9*3	2	18

^†

CYP2C9*1*1 - n = 142